Edgewise Therapeutics, Inc. Board of Directors

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Dr. Kevin Koch Ph.D.

Dr. Kevin Koch Ph.D.

President, CEO & Director

Dr. Peter A. Thompson FACP, M.D.

Dr. Peter A. Thompson FACP, M.D.

Co-Founder & Independent Chairman

Dr. Badreddin Edris Ph.D.

Dr. Badreddin Edris Ph.D.

Co-Founder & Independent Director

Mr. R. Michael Carruthers

Mr. R. Michael Carruthers

Chief Financial Officer

Dr. Alan J. Russell Ph.D.

Dr. Alan J. Russell Ph.D.

Co-Founder, Chief Scientific Officer & Director

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.